Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

Abstract

UNLABELLED Cisplatin-based chemotherapy is the standard of care for patients with muscle-invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, although molecular determinants of cisplatin response are incompletely understood. We performed whole-exome sequencing… (More)
DOI: 10.1158/2159-8290.CD-14-0623

Topics

Cite this paper

@article{Allen2014SomaticEM, title={Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.}, author={Eliezer M Van Allen and Kent W. Mouw and Philip Kim and Gopa Iyer and Nikhil Wagle and Hikmat A. Al-Ahmadie and Cong Zhu and Irina Ostrovnaya and Gregory V. Kryukov and Kevin W. O'Connor and John P. Sfakianos and Ilana Rebecca Garcia-Grossman and Jaegil Kim and Elizabeth A Guancial and Richard Bambury and Samira Bahl and Namrata Gupta and Deborah Farlow and Angela Q Qu and Sabina Signoretti and Justine A Barletta and Victor Reuter and Jesse Boehm and Michael Lawrence and Gad Getz and Philip W. Kantoff and Bernard H. Bochner and Toni K Choueiri and Dean F Bajorin and David B. Solit and Stacey Gabriel and Alan D'andrea and Levi A. Garraway and Jonathan E Rosenberg}, journal={Cancer discovery}, year={2014}, volume={4 10}, pages={1140-53} }